Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 86 entries
Sorted by: Best Match Show Resources per page
Corrigendum: Intronless WNT10B-short variant underlies new recurrent allele-specific rearrangement in acute myeloid leukaemia.

Scientific reports

Lazzaroni F, Giacco LD, Biasci D, Turrini M, Prosperi L, Brusamolino R, Cairoli R, Beghini A.
PMID: 28443613
Sci Rep. 2017 Apr 26;7:46788. doi: 10.1038/srep46788.

No abstract available.

Cite
Lazzaroni F, Giacco LD, Biasci D, et al. Corrigendum: Intronless WNT10B-short variant underlies new recurrent allele-specific rearrangement in acute myeloid leukaemia. Sci Rep. 2017;7:46788doi: 10.1038/srep46788.
Lazzaroni, F., Giacco, L. D., Biasci, D., Turrini, M., Prosperi, L., Brusamolino, R., Cairoli, R., & Beghini, A. (2017). Corrigendum: Intronless WNT10B-short variant underlies new recurrent allele-specific rearrangement in acute myeloid leukaemia. Scientific reports, 746788. https://doi.org/10.1038/srep46788
Lazzaroni, Francesca, et al. "Corrigendum: Intronless WNT10B-short variant underlies new recurrent allele-specific rearrangement in acute myeloid leukaemia." Scientific reports vol. 7 (2017): 46788. doi: https://doi.org/10.1038/srep46788
Lazzaroni F, Giacco LD, Biasci D, Turrini M, Prosperi L, Brusamolino R, Cairoli R, Beghini A. Corrigendum: Intronless WNT10B-short variant underlies new recurrent allele-specific rearrangement in acute myeloid leukaemia. Sci Rep. 2017 Apr 26;7:46788. doi: 10.1038/srep46788. PMID: 28443613; PMCID: PMC5405405.
Copy Download .nbib Format: NLM
NEPA, a new fixed combination of netupitant and palonosetron, is a cost-effective intervention for the prevention of chemotherapy-induced nausea and vomiting in the UK.

Drugs in context

Cawston H, Bourhis F, Eriksson J, Ruffo P, D'Agostino P, Turini M, Schwartzberg L, McGuire A.
PMID: 28392826
Drugs Context. 2017 Mar 24;6:212298. doi: 10.7573/dic.212298. eCollection 2017.

BACKGROUND: The objective was to evaluate the cost-effectiveness of NEPA, an oral fixed combination netupitant (NETU, 300 mg) and palonosetron (PA, 0.5 mg) compared with aprepitant and palonosetron (APPA) or palonosetron (PA) alone, to prevent chemotherapy-induced nausea and vomiting...

Cite
Cawston H, Bourhis F, Eriksson J, et al. NEPA, a new fixed combination of netupitant and palonosetron, is a cost-effective intervention for the prevention of chemotherapy-induced nausea and vomiting in the UK. Drugs Context. 2017;6:212298doi: 10.7573/dic.212298.
Cawston, H., Bourhis, F., Eriksson, J., Ruffo, P., D'Agostino, P., Turini, M., Schwartzberg, L., & McGuire, A. (2017). NEPA, a new fixed combination of netupitant and palonosetron, is a cost-effective intervention for the prevention of chemotherapy-induced nausea and vomiting in the UK. Drugs in context, 6212298. https://doi.org/10.7573/dic.212298
Cawston, Helene, et al. "NEPA, a new fixed combination of netupitant and palonosetron, is a cost-effective intervention for the prevention of chemotherapy-induced nausea and vomiting in the UK." Drugs in context vol. 6 (2017): 212298. doi: https://doi.org/10.7573/dic.212298
Cawston H, Bourhis F, Eriksson J, Ruffo P, D'Agostino P, Turini M, Schwartzberg L, McGuire A. NEPA, a new fixed combination of netupitant and palonosetron, is a cost-effective intervention for the prevention of chemotherapy-induced nausea and vomiting in the UK. Drugs Context. 2017 Mar 24;6:212298. doi: 10.7573/dic.212298. eCollection 2017. PMID: 28392826; PMCID: PMC5378057.
Copy Download .nbib Format: NLM
Gender differences in remission and recovery of schizophrenic and schizoaffective patients: preliminary results of a prospective cohort study.

Schizophrenia research and treatment

Carpiniello B, Pinna F, Tusconi M, Zaccheddu E, Fatteri F.
PMID: 22966440
Schizophr Res Treatment. 2012;2012:576369. doi: 10.1155/2012/576369. Epub 2012 Jan 16.

The aim of the paper was to evaluate rates of clinical remission and recovery according to gender in a cohort of chronic outpatients attending a university community mental health center who had been diagnosed with schizophrenia and schizoaffective disorder...

Cite
Carpiniello B, Pinna F, Tusconi M, et al. Gender differences in remission and recovery of schizophrenic and schizoaffective patients: preliminary results of a prospective cohort study. Schizophr Res Treatment. 2012;2012:576369doi: 10.1155/2012/576369.
Carpiniello, B., Pinna, F., Tusconi, M., Zaccheddu, E., & Fatteri, F. (2012). Gender differences in remission and recovery of schizophrenic and schizoaffective patients: preliminary results of a prospective cohort study. Schizophrenia research and treatment, 2012576369. https://doi.org/10.1155/2012/576369
Carpiniello, Bernardo, et al. "Gender differences in remission and recovery of schizophrenic and schizoaffective patients: preliminary results of a prospective cohort study." Schizophrenia research and treatment vol. 2012 (2012): 576369. doi: https://doi.org/10.1155/2012/576369
Carpiniello B, Pinna F, Tusconi M, Zaccheddu E, Fatteri F. Gender differences in remission and recovery of schizophrenic and schizoaffective patients: preliminary results of a prospective cohort study. Schizophr Res Treatment. 2012;2012:576369. doi: 10.1155/2012/576369. Epub 2012 Jan 16. PMID: 22966440; PMCID: PMC3420715.
Copy Download .nbib Format: NLM
Control of excitable pulses in an injection-locked semiconductor laser.

Physical review. E, Statistical, nonlinear, and soft matter physics

Turconi M, Garbin B, Feyereisen M, Giudici M, Barland S.
PMID: 24032917
Phys Rev E Stat Nonlin Soft Matter Phys. 2013 Aug;88(2):022923. doi: 10.1103/PhysRevE.88.022923. Epub 2013 Aug 30.

In spite of numerous theoretical and experimental reports of excitability in lasers with injected signal based on the locking-unlocking transition, the response of the system to controlled external perturbations (which is at the basis of the definition of excitable...

Cite
Turconi M, Garbin B, Feyereisen M, et al. Control of excitable pulses in an injection-locked semiconductor laser. Phys Rev E Stat Nonlin Soft Matter Phys. 2013;88(2):022923doi: 10.1103/PhysRevE.88.022923.
Turconi, M., Garbin, B., Feyereisen, M., Giudici, M., & Barland, S. (2013). Control of excitable pulses in an injection-locked semiconductor laser. Physical review. E, Statistical, nonlinear, and soft matter physics, 88(2), 022923. https://doi.org/10.1103/PhysRevE.88.022923
Turconi, M, et al. "Control of excitable pulses in an injection-locked semiconductor laser." Physical review. E, Statistical, nonlinear, and soft matter physics vol. 88,2 (2013): 022923. doi: https://doi.org/10.1103/PhysRevE.88.022923
Turconi M, Garbin B, Feyereisen M, Giudici M, Barland S. Control of excitable pulses in an injection-locked semiconductor laser. Phys Rev E Stat Nonlin Soft Matter Phys. 2013 Aug;88(2):022923. doi: 10.1103/PhysRevE.88.022923. Epub 2013 Aug 30. PMID: 24032917.
Copy Download .nbib Format: NLM
Management of multiple sclerosis patients in central European countries: current needs and potential solutions.

Therapeutic advances in neurological disorders

Berger T, Adamczyk-Sowa M, Csépány T, Fazekas F, Hojs Fabjan T, Horáková D, Illes Z, Klimová E, Leutmezer F, Rejdak K, Rozsa C, Šega Jazbec S, Szilasiová J, Turčáni P, Vachová M, Vécsei L, Havrdová E.
PMID: 29511382
Ther Adv Neurol Disord. 2018 Feb 22;11:1756286418759189. doi: 10.1177/1756286418759189. eCollection 2018.

Multiple sclerosis (MS) experts in Europe are facing rapidly rising demands of excellence due to the increasing complexity of MS therapy and management. A central European expert board of MS experts met to identify needs and obstacles with respect...

Cite
Berger T, Adamczyk-Sowa M, Csépány T, et al. Management of multiple sclerosis patients in central European countries: current needs and potential solutions. Ther Adv Neurol Disord. 2018;11:1756286418759189doi: 10.1177/1756286418759189.
Berger, T., Adamczyk-Sowa, M., Csépány, T., Fazekas, F., Hojs Fabjan, T., Horáková, D., Illes, Z., Klimová, E., Leutmezer, F., Rejdak, K., Rozsa, C., Šega Jazbec, S., Szilasiová, J., Turčáni, P., Vachová, M., Vécsei, L., & Havrdová, E. (2018). Management of multiple sclerosis patients in central European countries: current needs and potential solutions. Therapeutic advances in neurological disorders, 111756286418759189. https://doi.org/10.1177/1756286418759189
Berger, Thomas, et al. "Management of multiple sclerosis patients in central European countries: current needs and potential solutions." Therapeutic advances in neurological disorders vol. 11 (2018): 1756286418759189. doi: https://doi.org/10.1177/1756286418759189
Berger T, Adamczyk-Sowa M, Csépány T, Fazekas F, Hojs Fabjan T, Horáková D, Illes Z, Klimová E, Leutmezer F, Rejdak K, Rozsa C, Šega Jazbec S, Szilasiová J, Turčáni P, Vachová M, Vécsei L, Havrdová E. Management of multiple sclerosis patients in central European countries: current needs and potential solutions. Ther Adv Neurol Disord. 2018 Feb 22;11:1756286418759189. doi: 10.1177/1756286418759189. eCollection 2018. PMID: 29511382; PMCID: PMC5826096.
Copy Download .nbib Format: NLM
An assessment of chemotherapy-induced nausea and vomiting direct costs in three EU countries.

Drugs in context

Turini M, Piovesana V, Ruffo P, Ripellino C, Cataldo N.
PMID: 26322114
Drugs Context. 2015 Jul 28;4:212285. doi: 10.7573/dic.212285. eCollection 2015.

BACKGROUND: chemotherapy-induced nausea and vomiting (CINV) has been commonly reported as one of the most distressing adverse effects among treated patients with cancer. Inadequately treated, CINV can lead to increased resource utilization and severely impair patients' daily functioning and...

Cite
Turini M, Piovesana V, Ruffo P, et al. An assessment of chemotherapy-induced nausea and vomiting direct costs in three EU countries. Drugs Context. 2015;4:212285doi: 10.7573/dic.212285.
Turini, M., Piovesana, V., Ruffo, P., Ripellino, C., & Cataldo, N. (2015). An assessment of chemotherapy-induced nausea and vomiting direct costs in three EU countries. Drugs in context, 4212285. https://doi.org/10.7573/dic.212285
Turini, Marco, et al. "An assessment of chemotherapy-induced nausea and vomiting direct costs in three EU countries." Drugs in context vol. 4 (2015): 212285. doi: https://doi.org/10.7573/dic.212285
Turini M, Piovesana V, Ruffo P, Ripellino C, Cataldo N. An assessment of chemotherapy-induced nausea and vomiting direct costs in three EU countries. Drugs Context. 2015 Jul 28;4:212285. doi: 10.7573/dic.212285. eCollection 2015. PMID: 26322114; PMCID: PMC4544273.
Copy Download .nbib Format: NLM
Rheological Issues on Oropharyngeal Dysphagia.

Dysphagia

Gallegos C, Turcanu M, Assegehegn G, Brito-de la Fuente E.
PMID: 34216239
Dysphagia. 2021 Jul 03; doi: 10.1007/s00455-021-10337-w. Epub 2021 Jul 03.

There is an increasing proof of the relevance of rheology on the design of fluids for the diagnosis and management of dysphagia. In this sense, different authors have reported clinical evidence that support the conclusion that an increase in...

Cite
Gallegos C, Turcanu M, Assegehegn G, et al. Rheological Issues on Oropharyngeal Dysphagia. Dysphagia. 2021;doi: 10.1007/s00455-021-10337-w.
Gallegos, C., Turcanu, M., Assegehegn, G., & Brito-de la Fuente, E. (2021). Rheological Issues on Oropharyngeal Dysphagia. Dysphagia, . https://doi.org/10.1007/s00455-021-10337-w
Gallegos, Crispulo, et al. "Rheological Issues on Oropharyngeal Dysphagia." Dysphagia vol. (2021). doi: https://doi.org/10.1007/s00455-021-10337-w
Gallegos C, Turcanu M, Assegehegn G, Brito-de la Fuente E. Rheological Issues on Oropharyngeal Dysphagia. Dysphagia. 2021 Jul 03; doi: 10.1007/s00455-021-10337-w. Epub 2021 Jul 03. PMID: 34216239.
Copy Download .nbib Format: NLM
Sustained symptomatic remission in schizophrenia: Course and predictors from a two-year prospective study.

Schizophrenia research

Carpiniello B, Pinna F, Manchia M, Tusconi M, Cavallaro R, Bosia M.
PMID: 34839071
Schizophr Res. 2021 Nov 25;239:34-41. doi: 10.1016/j.schres.2021.11.023. Epub 2021 Nov 25.

BACKGROUND: Although remission is a priority target in psychosis, reported rates show a marked variation across studies and instability over time. Such variability, partly due to methodology, emphasizes the need to define the optimal assessment procedure, as well as...

Cite
Carpiniello B, Pinna F, Manchia M, et al. Sustained symptomatic remission in schizophrenia: Course and predictors from a two-year prospective study. Schizophr Res. 2021;239:34-41doi: 10.1016/j.schres.2021.11.023.
Carpiniello, B., Pinna, F., Manchia, M., Tusconi, M., Cavallaro, R., & Bosia, M. (2021). Sustained symptomatic remission in schizophrenia: Course and predictors from a two-year prospective study. Schizophrenia research, 23934-41. https://doi.org/10.1016/j.schres.2021.11.023
Carpiniello, Bernardo, et al. "Sustained symptomatic remission in schizophrenia: Course and predictors from a two-year prospective study." Schizophrenia research vol. 239 (2021): 34-41. doi: https://doi.org/10.1016/j.schres.2021.11.023
Carpiniello B, Pinna F, Manchia M, Tusconi M, Cavallaro R, Bosia M. Sustained symptomatic remission in schizophrenia: Course and predictors from a two-year prospective study. Schizophr Res. 2021 Nov 25;239:34-41. doi: 10.1016/j.schres.2021.11.023. Epub 2021 Nov 25. PMID: 34839071.
Copy Download .nbib Format: NLM
Eltrombopag as second line treatment in patients with primary immune thrombocytopenia: A single center real life experience.

Blood cells, molecules & diseases

Gardellini A, Guidotti F, Feltri M, Zancanella M, Maino E, Ambrosiani L, Turrini M.
PMID: 34715450
Blood Cells Mol Dis. 2021 Dec;92:102620. doi: 10.1016/j.bcmd.2021.102620. Epub 2021 Oct 21.

Glucocorticoid treatment is the standard initial therapy for patients with immune thrombocytopenia (ITP). Despite a rate of 60-80% of initial remissions, only 30 to 50% of adults have a sustained response after discontinuation. Second line options are splenectomy, thrombopoietin-receptor...

Cite
Gardellini A, Guidotti F, Feltri M, et al. Eltrombopag as second line treatment in patients with primary immune thrombocytopenia: A single center real life experience. Blood Cells Mol Dis. 2021;92:102620doi: 10.1016/j.bcmd.2021.102620.
Gardellini, A., Guidotti, F., Feltri, M., Zancanella, M., Maino, E., Ambrosiani, L., & Turrini, M. (2021). Eltrombopag as second line treatment in patients with primary immune thrombocytopenia: A single center real life experience. Blood cells, molecules & diseases, 92102620. https://doi.org/10.1016/j.bcmd.2021.102620
Gardellini, Angelo, et al. "Eltrombopag as second line treatment in patients with primary immune thrombocytopenia: A single center real life experience." Blood cells, molecules & diseases vol. 92 (2021): 102620. doi: https://doi.org/10.1016/j.bcmd.2021.102620
Gardellini A, Guidotti F, Feltri M, Zancanella M, Maino E, Ambrosiani L, Turrini M. Eltrombopag as second line treatment in patients with primary immune thrombocytopenia: A single center real life experience. Blood Cells Mol Dis. 2021 Dec;92:102620. doi: 10.1016/j.bcmd.2021.102620. Epub 2021 Oct 21. PMID: 34715450.
Copy Download .nbib Format: NLM
The first case of .

Access microbiology

Congedo P, Gardellini A, Corich L, Papa A, Turrini M.
PMID: 33195975
Access Microbiol. 2020 Aug 25;2(10):acmi000161. doi: 10.1099/acmi.0.000161. eCollection 2020.

No abstract available.

Cite
Congedo P, Gardellini A, Corich L, et al. The first case of . Access Microbiol. 2020;2(10):acmi000161doi: 10.1099/acmi.0.000161.
Congedo, P., Gardellini, A., Corich, L., Papa, A., & Turrini, M. (2020). The first case of . Access microbiology, 2(10), acmi000161. https://doi.org/10.1099/acmi.0.000161
Congedo, Pierluigi, et al. "The first case of ." Access microbiology vol. 2,10 (2020): acmi000161. doi: https://doi.org/10.1099/acmi.0.000161
Congedo P, Gardellini A, Corich L, Papa A, Turrini M. The first case of . Access Microbiol. 2020 Aug 25;2(10):acmi000161. doi: 10.1099/acmi.0.000161. eCollection 2020. PMID: 33195975; PMCID: PMC7660240.
Copy Download .nbib Format: NLM
Author Correction: Hydrophilic microporous membranes for selective ion separation and flow-battery energy storage.

Nature materials

Tan R, Wang A, Malpass-Evans R, Williams R, Zhao EW, Liu T, Ye C, Zhou X, Darwich BP, Fan Z, Turcani L, Jackson E, Chen L, Chong SY, Li T, Jelfs KE, Cooper AI, Brandon NP, Grey CP, McKeown NB, Song Q.
PMID: 31866669
Nat Mater. 2020 Feb;19(2):251. doi: 10.1038/s41563-019-0593-z.

An amendment to this paper has been published and can be accessed via a link at the top of the paper.

Cite
Tan R, Wang A, Malpass-Evans R, et al. Author Correction: Hydrophilic microporous membranes for selective ion separation and flow-battery energy storage. Nat Mater. 2020;19(2):251doi: 10.1038/s41563-019-0593-z.
Tan, R., Wang, A., Malpass-Evans, R., Williams, R., Zhao, E. W., Liu, T., Ye, C., Zhou, X., Darwich, B. P., Fan, Z., Turcani, L., Jackson, E., Chen, L., Chong, S. Y., Li, T., Jelfs, K. E., Cooper, A. I., Brandon, N. P., Grey, C. P., McKeown, N. B., & Song, Q. (2020). Author Correction: Hydrophilic microporous membranes for selective ion separation and flow-battery energy storage. Nature materials, 19(2), 251. https://doi.org/10.1038/s41563-019-0593-z
Tan, Rui, et al. "Author Correction: Hydrophilic microporous membranes for selective ion separation and flow-battery energy storage." Nature materials vol. 19,2 (2020): 251. doi: https://doi.org/10.1038/s41563-019-0593-z
Tan R, Wang A, Malpass-Evans R, Williams R, Zhao EW, Liu T, Ye C, Zhou X, Darwich BP, Fan Z, Turcani L, Jackson E, Chen L, Chong SY, Li T, Jelfs KE, Cooper AI, Brandon NP, Grey CP, McKeown NB, Song Q. Author Correction: Hydrophilic microporous membranes for selective ion separation and flow-battery energy storage. Nat Mater. 2020 Feb;19(2):251. doi: 10.1038/s41563-019-0593-z. PMID: 31866669.
Copy Download .nbib Format: NLM
Increased Endogenous GDNF in Mice Protects Against Age-Related Decline in Neuronal Cholinergic Markers.

Frontiers in aging neuroscience

Mitra S, Turconi G, Darreh-Shori T, Mätlik K, Aquilino M, Eriksdotter M, Andressoo JO.
PMID: 34475820
Front Aging Neurosci. 2021 Aug 12;13:714186. doi: 10.3389/fnagi.2021.714186. eCollection 2021.

Gradual decline in cholinergic transmission and cognitive function occurs during normal aging, whereas pathological loss of cholinergic function is a hallmark of different types of dementia, including Alzheimer's disease (AD), Lewy body dementia (LBD), and Parkinson's disease dementia (PDD)....

Cite
Mitra S, Turconi G, Darreh-Shori T, et al. Increased Endogenous GDNF in Mice Protects Against Age-Related Decline in Neuronal Cholinergic Markers. Front Aging Neurosci. 2021;13:714186doi: 10.3389/fnagi.2021.714186.
Mitra, S., Turconi, G., Darreh-Shori, T., Mätlik, K., Aquilino, M., Eriksdotter, M., & Andressoo, J. O. (2021). Increased Endogenous GDNF in Mice Protects Against Age-Related Decline in Neuronal Cholinergic Markers. Frontiers in aging neuroscience, 13714186. https://doi.org/10.3389/fnagi.2021.714186
Mitra, Sumonto, et al. "Increased Endogenous GDNF in Mice Protects Against Age-Related Decline in Neuronal Cholinergic Markers." Frontiers in aging neuroscience vol. 13 (2021): 714186. doi: https://doi.org/10.3389/fnagi.2021.714186
Mitra S, Turconi G, Darreh-Shori T, Mätlik K, Aquilino M, Eriksdotter M, Andressoo JO. Increased Endogenous GDNF in Mice Protects Against Age-Related Decline in Neuronal Cholinergic Markers. Front Aging Neurosci. 2021 Aug 12;13:714186. doi: 10.3389/fnagi.2021.714186. eCollection 2021. PMID: 34475820; PMCID: PMC8406776.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 86 entries